Company Overview and News
Analysts say the surge has been fuelled by a land auction at the site of the city’s former airport which fetched HK$25.16 billion, a record price for a residential plot
One of the city’s largest land owners won the 14th government tender by paying a record HK$25.1 billion for a plot with gross floor area of 1.42 million sq ft
Developers are forming consortiums to spread the financial risk of bidding for a residential site that could fetch an estimated US$3.25 billion
Close to 300 flats lie disturbingly vacant in a completed new residential development in Ho Man Tin even as the Hong Kong government struggles to resolve the perennial short supply of housing in the world’s most expensive property market.
KUALA LUMPUR: Malaysian tycoon Robert Kuok has been thrust into the political spotlight after he was accused of funding the opposition in Malaysia in a bid to set up a Chinese-based government.
Hong Kong homebuilders are expected to report strong half-year and full-year earnings during the coming weeks as home prices continued to soar and sales of new flats climbed to a decade high.
LAST year was dotted by the return of higher commodity prices and better economic growth. The world’s economies on average are back in business as growth rates and trade have started to improve once again after some period of uncertainty caused by a cooling China economy and also the slump in global crude oil prices.
Developers’ enthusiasm for land tenders has shown no signs of easing – a residential site in Hong Kong’s Kwun Tong has attracted stronger than expected interest. But valuers said infrastructure in the region might not be able to support the extra population.
Wharf pays HK$12.45 billion, or HK$28,530 per sq ft for the plot, smashing the previous record of HK$21,016 per sq ft for Kowloon
The buying fell for the first time in the past five weeks while the selling among directors surged for the second straight week based on filings on the Hong Kong stock exchange from January 8 to 12. A total of 47 companies recorded 200 purchases worth HK$129 million (US$16.5 million) versus 28 firms with 117 disposals worth HK$328 million. The buy figures were down from the previous week’s four-day total of 48 companies, 207 purchases and HK$173 million.
Sun Hung Kai Properties and Kerry Properties launch first projects of the year in Ma On Shan and Ho Man Tin
Company snaps up a seventh site this year, to be redeveloped into a residential complex in partnership with electric utility CLP
Flats to be built on land at Wong Chuk Hang are likely to fetch prices similar to those in the city’s more traditional upmarket areas, analysts forecast
After the price of an adjacent plot beats expectations, some analysts see the possibility of a fresh high in a city already among the world’s costliest to buy a home
Rents at APM, Sun Hung Kai Properties’s flagship mall in Kowloon East, have gone up by as much as 15 per cent as leases have come up for renewal this year.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...